scholarly journals Single center experience on the production of fluorine-18 radiopharmaceuticals using a 7.5 MeV cyclotron: capabilities and challenges

2020 ◽  
Vol 2 (5) ◽  
Author(s):  
Andreas Fesas ◽  
Mohammad Reza Pourkhessalian ◽  
Alexis Vrachimis
Keyword(s):  
Radiochemical Yield ◽  
Low Energy ◽  
Third Party ◽  
Single Center ◽  
Single Patient ◽  
Remote Site ◽  
On Demand ◽  
Single Center Experience ◽  
Radiochemical Yields ◽  
House Production

Abstract A plethora of cyclotron options have been developed to fulfil the demands of nuclear medicine industries in PET and SPECT radioisotopes. As a remote site, the difficulties of transporting fluorine 18 radiopharmaceuticals for PET examinations were overcome by the installation of a 7.5 MeV cyclotron for in-house production. The addition of a third-party synthesis module enabled the synthesis of 7 additional radiotracers according to a ‘’dose on demand’’ principle. Radiochemical yield is considered the primary factor in producing sufficient activity for a single patient dose, since low energy cyclotrons can only offer low initial activities. We hereby report the average radiochemical yields, synthesis times and doses per production for [18F]FDG, [18F]PSMA-1007, [18F]DOPA, [18F]FET, [18F]FLT, [18F]FMISO, [18F]Choline and [18F]FES using a BG75 cyclotron and a Neptis Mosaic-RS. Additionally, the presence of radionuclidic impurities in the final product was examined.

scholarly journals Late Retrieval of the Leadless Micra Transcatheter Pacemaker System

2021 ◽  
Vol 04 (06) ◽  
pp. 01-13
Author(s):  
Kentaro Minami
Keyword(s):  
Success Rate ◽  
Biventricular Pacing ◽  
Intracardiac Echocardiography ◽  
Surrounding Tissue ◽  
Single Center ◽  
Single Patient ◽  
Cardiac Wall ◽  
Single Center Experience ◽  
Pacemaker Syndrome ◽  
Leadless Pacing

Aim: We report our single-center experience with the retrieval and replacement of the chronically implanted Micra transcatheter pacing system (TPS). Material and Methods: We included 6 patients with an implanted the Micra TPSs who subsequently underwent transvenous method of retrieval at our institution. The indication for device retrieval was pacemaker syndrome in two patients, battery depletion in three patients, and need for upgrade to biventricular pacing in one patient. Results: After an implantation duration of 555 ± 373 days, the overall retrieval success rate was 83.3%, 5 of 6 patients. No procedure-related adverse device events occurred. In the single patient with unsuccessful retrieval, intracardiac echocardiography revealed that the Micra TPS was embedded within the cardiac wall and surrounding tissue. After retrieval, four patients received a new Micra TPS. Conclusions: Late retrieval of an implanted Micra TPS was safe and feasible, which indicates the possibility for their safe and elective replacement with a new leadless pacing device.

scholarly journals Ivacaftor Therapy in CF Patients: Single Center Experience

2014 ◽  
Vol 2014 ◽  
pp. 1-5
Author(s):  
Pritish Mondal ◽  
Amber Loyson ◽  
Jorge Lascano ◽  
Satyanarayan Hegde
Keyword(s):  
Cystic Fibrosis ◽  
Lung Function ◽  
Lung Disease ◽  
Case Series ◽  
Forced Expiratory Volume ◽  
Third Party ◽  
Normal Lung ◽  
Single Center ◽  
Single Center Experience ◽  
Pediatric Age Group

Ivacaftor is the first novel cystic fibrosis pharmaceutical that acts at the molecular level to potentiate cystic fibrosis transmembrane conductance regulator (CFTR) function and was first approved for clinical use in 2012. We are sharing our single center experience of five patients: four from pediatric age group and one adult patient. All patients had both subjective and objective improvements in their health. Despite established lung disease, our patients had significant improvement in both their FEV1 (forced expiratory volume in 1 second) and FEF25–75and BMI (body mass index). Larger studies demonstrated only 6.7% improvement in mean FEV1 after starting Ivacaftor therapy but their patient population had normal lung function to begin with. In contrast our case series demonstrates that, in patients with established lung disease and diminished lung function, Ivacaftor can be expected to result in much higher recovery in lung function. Mean FEV1 improved by 35% in our case series. Ivacaftor is extremely expensive, costing $300,000 per patient per year requiring lifelong therapy, hence requiring prior authorizations from most third-party payers in the USA. The knowledge shared from our experience will be useful for other clinicians to petition healthcare policymakers on behalf of their patients.

Sign in / Sign up

Export Citation Format

Share Document